ZyVersa Therapeutics approves 1-for-35 reverse stock split and increases authorized shares to 251M

ZyVersa Therapeutics, Inc.

Reverse split 1:35 effective Dec 4, 2023 at 4:01 pm ET; adjusted trading begins Dec 5 under ZVSA.
Authorized common shares increased from 110M to 250M; total capital stock from 111M to 251M.
Split intended to meet Nasdaq's $1.00 minimum bid price requirement for continued listing.
No fractional shares will be issued; holders will receive rounding to nearest whole share.
Proportional adjustments to equity awards, warrants, and convertible securities.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ZyVersa Therapeutics, Inc.: Certificate of amendment to effect a 1-for-35 reverse stock split and increase authorized capital stock from 111,000,000 to 251,000,000 shares (effective 2023-12-04).

Change: charter amendment
Effective: 2023-12-04

Exact text from the filing

On November 30, 2023, ZyVersa Therapeutics, Inc. (the “Company”) filed a certificate of amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware relating to a 1-for-35 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock (“Common Stock”).

View on SEC.gov

Browse all governance changes →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-043170

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.